Literature DB >> 23997049

Severe refractory asthma: an update.

Reinier R L Wener1, Elisabeth H Bel.   

Abstract

Asthma is a heterogeneous disease in which adequate asthma control cannot be achieved in a substantial proportion despite currently available treatment possibilities. This subgroup has been defined as "severe refractory" asthma. Over the past years considerable progress has been made regarding a more exact definition of severe refractory asthma. A systematic approach to evaluate the asthma patient has been postulated. Further detailed classification into distinct phenotypes is ongoing to target the right treatment to the right patient. And, new therapeutic targeted treatment options are currently in development to provide possible new targets to improve disease state, symptoms and quality of life. This review will provide an update on the latest advancements with regard to all these domains.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23997049     DOI: 10.1183/09059180.00001913

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  14 in total

1.  Clinical heterogeneity in the severe asthma research program.

Authors:  Wendy C Moore; Anne M Fitzpatrick; Xingnan Li; Annette T Hastie; Huashi Li; Deborah A Meyers; Eugene R Bleecker
Journal:  Ann Am Thorac Soc       Date:  2013-12

2.  The airway microbiome in patients with severe asthma: Associations with disease features and severity.

Authors:  Yvonne J Huang; Snehal Nariya; Jeffrey M Harris; Susan V Lynch; David F Choy; Joseph R Arron; Homer Boushey
Journal:  J Allergy Clin Immunol       Date:  2015-07-26       Impact factor: 10.793

3.  PILL Series. The 'problematic' asthma patient.

Authors:  Swee Leng Kui; Choon How How; Jansen Koh
Journal:  Singapore Med J       Date:  2015-07       Impact factor: 1.858

4.  Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma.

Authors:  Tamer Y El Mays; Parichita Choudhury; Richard Leigh; Emmanuel Koumoundouros; Joanne Van der Velden; Grishma Shrestha; Cora A Pieron; John H Dennis; Francis Hy Green; Ken J Snibson
Journal:  Respir Res       Date:  2014-09-16

5.  Prevalence and severity of asthmatic symptoms in Grenadian school children: the Grenada National Asthma Survey.

Authors:  D Thongkham; J Tran; M T Clunes; F Brahim
Journal:  BMJ Open       Date:  2015-10-19       Impact factor: 2.692

6.  The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis.

Authors:  L E Barry; J Sweeney; C O'Neill; D Price; L G Heaney
Journal:  Respir Res       Date:  2017-06-26

Review 7.  Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.

Authors:  Virginia Mirra; Silvia Montella; Francesca Santamaria
Journal:  BMC Pediatr       Date:  2018-02-21       Impact factor: 2.125

8.  Altered Innate Immune Responses in Neutrophils from Patients with Well- and Suboptimally Controlled Asthma.

Authors:  Francesca S M Tang; Gloria J Foxley; Peter G Gibson; Janette K Burgess; Katherine J Baines; Brian G Oliver
Journal:  Mediators Inflamm       Date:  2015-11-18       Impact factor: 4.711

9.  Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.

Authors:  Tao Zhu; Xiao-Ling Wu; Wei Zhang; Min Xiao
Journal:  Int J Mol Sci       Date:  2015-08-26       Impact factor: 5.923

10.  A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers.

Authors:  Francis H Y Green; Richard Leigh; Morenike Fadayomi; Gurkeet Lalli; Andrea Chiu; Grishma Shrestha; Sharif G ElShahat; David Evan Nelson; Tamer Y El Mays; Cora A Pieron; John H Dennis
Journal:  Trials       Date:  2016-07-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.